Leukemia Clinical Trials in Colorado

Showing 1221-1240 of 1,550 trials

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205

This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study of dexmedetomidine versus placebo, with lorazepam rescue, for the management of severe alcohol withdrawal syndrome (AWS) and alcohol withdrawal delirium (AWD) in critically ill adults. The investigators hypothesize that the integration of dexmedetomidine (Precedex®) with usual therapy for the management of severe alcohol withdrawal syndrome (AWS) and alcohol withdrawal delirium/delirium tremens (AWD) in critically ill adult patients will reduce the time to resolution of AWS/AWD, increase the number of delirium-free and ventilator-free days in the first 28 days of hospitalization, reduce the length of ICU and hospital stays, and improve neurocognitive and quality of life scores on hospital discharge.

Alcohol Withdrawal DeliriumAlcohol Withdrawal Associated Autonomic HyperactivityAlcohol Withdrawal Hallucinosis+1 more

Denver Health and Hospital Authority49 participantsStarted Mar 2012

Colorado Springs, Colorado, United States • Colorado Springs, Colorado, United States • Denver, Colorado, United States +4 more locations

COMPLETEDPhase 150 miles

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

NCT00455052

This amended expansion phase of the protocol is to further the experience at a dose level of 150 mg CPT eq/m2 in patients with Stage IV non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and to test for preliminary anti-tumor activity in these tumor types. The MTD was initially defined as 113 mg CPT equivalents(eq)/m2 in the dose escalation part of the study. However, in the initial expansion phase (Protocol Amendment 11), 11 patients (10 NSCLC patients and 1 gastric cancer patients) were dosed at 113 mg CPT eq/m2 and less bone marrow toxicity was observed as compared to more heavily pre-treated patients in the dose escalation part of the study. Therefore, this amended expansion phase will investigate the safety and anti-tumor effects of a dose of 150 mg CPT eq/m2. The study will also determine: * The safety and tolerability of XMT-1001 at 150 mg CPT eq/m2 * The pharmacokinetics (PK) of XMT-1001 (how XMT-1001 behaves in the body) in patients Stage IV non-small cell lung carcinoma (NSCLC) and small cell lung cancer * Evidence of XMT-1001 anti-tumor activity at 150 mg CPT eq/m2

Small Cell Lung CancerNon-small Cell Lung Cancer

Mersana Therapeutics30 participantsStarted Mar 2011

Scottsdale, Arizona, United States • Denver, Colorado, United States • Indianapolis, Indiana, United States +9 more locations

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Leukemia Trials in Other Cities

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

A Study of DCC-2701 in Participants With Advanced Solid Tumors

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Expanded Access Program of Ponatinib

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

A Safety Study of SGN-CD33A in AML Patients

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

TR(ACE) Assay Clinical Specimen Study

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Other Conditions in Colorado